These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10634324)

  • 1. Loss of nerve: a molecular approach to better treatment of chronic pain.
    Friedrich MJ
    JAMA; 2000 Jan; 283(2):187-8. PubMed ID: 10634324
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuropeptide-toxin conjugates in pain research and treatment.
    Wiley RG
    Reg Anesth Pain Med; 2000; 25(5):546-8. PubMed ID: 11009244
    [No Abstract]   [Full Text] [Related]  

  • 3. Saporin immunotoxins.
    Flavell DJ
    Curr Top Microbiol Immunol; 1998; 234():57-61. PubMed ID: 9670612
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
    Wawrzynczak EJ; Cumber AJ; Henry RV; May J; Newell DR; Parnell GD; Worrell NR; Forrester JA
    Cancer Res; 1990 Dec; 50(23):7519-26. PubMed ID: 2253201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
    Tazzari PL; Bolognesi A; de Totero D; Falini B; Lemoli RM; Soria MR; Pileri S; Gobbi M; Stein H; Flenghi L
    Br J Haematol; 1992 Jun; 81(2):203-11. PubMed ID: 1322690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of immunotoxins bearing a single saporin molecule with multiple toxin conjugates.
    Flavell DJ; Flavell SU
    Methods Mol Biol; 2001; 166():87-100. PubMed ID: 11217378
    [No Abstract]   [Full Text] [Related]  

  • 7. Pain control: breaking the circuit.
    Hunt SP
    Trends Pharmacol Sci; 2000 Aug; 21(8):284-7. PubMed ID: 10918627
    [No Abstract]   [Full Text] [Related]  

  • 8. Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies.
    Ferrini S; Sforzini S; Canevari S
    Methods Mol Biol; 2001; 166():177-92. PubMed ID: 11217367
    [No Abstract]   [Full Text] [Related]  

  • 9. Hodgkin's disease. Future treatment strategies: fact or fiction?
    Schnell R; Barth S; Diehl V; Engert A
    Baillieres Clin Haematol; 1996 Sep; 9(3):573-93. PubMed ID: 8922247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmission of chronic nociception by spinal neurons expressing the substance P receptor.
    Nichols ML; Allen BJ; Rogers SD; Ghilardi JR; Honore P; Luger NM; Finke MP; Li J; Lappi DA; Simone DA; Mantyh PW
    Science; 1999 Nov; 286(5444):1558-61. PubMed ID: 10567262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good pain, bad pain.
    Iadarola JM; Caudle RM
    Science; 1997 Oct; 278(5336):239-40. PubMed ID: 9340772
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties.
    Kawakami K; Nakajima O; Morishita R; Nagai R
    ScientificWorldJournal; 2006 Jul; 6():781-90. PubMed ID: 16830050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.
    Tazzari PL; de Totero D; Bolognesi A; Testoni N; Pileri S; Roncella S; Reato G; Stein H; Gobbi M; Stirpe F
    Haematologica; 1999 Nov; 84(11):988-95. PubMed ID: 10553158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor.
    Mantyh PW; Rogers SD; Honore P; Allen BJ; Ghilardi JR; Li J; Daughters RS; Lappi DA; Wiley RG; Simone DA
    Science; 1997 Oct; 278(5336):275-9. PubMed ID: 9323204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: in vitro results and in vivo effects in an acute rejection model.
    Tazzari PL; Polito L; Bolognesi A; Pistillo MP; Capanni P; Palmisano GL; Lemoli RM; Curti A; Biancone L; Camussi G; Conte R; Ferrara GB; Stirpe F
    J Immunol; 2001 Oct; 167(8):4222-9. PubMed ID: 11591743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
    Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
    J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conserved amino acid residues in ribosome-inactivating proteins from plants.
    Funatsu G; Islam MR; Minami Y; Sung-Sil K; Kimura M
    Biochimie; 1991; 73(7-8):1157-61. PubMed ID: 1742358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin.
    Stirpe F; Wawrzynczak EJ; Brown AN; Knyba RE; Watson GJ; Barbieri L; Thorpe PE
    Br J Cancer; 1988 Nov; 58(5):558-61. PubMed ID: 3265330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin.
    Glennie MJ; McBride HM; Stirpe F; Thorpe PE; Worth AT; Stevenson GT
    J Exp Med; 1987 Jul; 166(1):43-62. PubMed ID: 3110351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotoxin construction with a ribosome-inactivating protein from barley.
    Ebert RF; Spryn LA
    Bioconjug Chem; 1990; 1(5):331-6. PubMed ID: 2098110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.